This CPB has been revised with the following: (i) for Crohn's disease (CD), (a) initial criteria, revised to include either ‘inadequate response to systemic corticosteroids, thiopurines (e.g., azathioprine, mercaptopurine), or methotrexate’; or ‘intolerance or contraindication to systemic corticosteroids, thiopurines (e.g., azathioprine, mercaptopurine), and methotrexate (see Appendix), and (b) continuation of risankizumab-rzaa (Skyrizi) therapy, added improvement of appearance of the mucosa on endoscopy, computed tomography enterography (CTE), or magnetic resonance enterography (MRE) from baseline; and (ii) consolidated the appendix to include 'Examples of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, Cyclosporine, Acitretin, or Leflunomide'.